Subject:Estimatedsales revenue for Q3 2025 amounted to PLN 7.2 million - a 38%year-on-year increaseCurrentReport No.:30/2025Dateof preparation:6 October 2025Legalbasis:Article 17(1) of the MAR Regulation - inside information

MedicalgorithmicsS.A., with its registered office in Warsaw (the "Company",the "Issuer"), hereby announces that in the third quarter of 2025, theestimated, unaudited consolidatedsales revenue of the MedicalgorithmicsGroup amounted to a total of PLN 7,173 thousand, including PLN 2,181thousand generated in the U.S. market.

Thenumber of sessions, i.e.ECG analyses performed using the Company's systems during the period,reached 96,617.

Forcomparison, in the third quarter of the previous calendar year, thesefigures were as follows: sales revenue of PLN 5,212 thousand,including PLN 1,238 thousand in the U.S. market; the number ofsessions in that period amounted to 72,400.

TheManagement Board of the Company emphasizes that this report containsestimated data, which may be subject to change following furtheraccounting workandthe settlement of sales with partners for the third quarter of 2025.Finaldata on the consolidatedsalesrevenue achieved in the third quarter of 2025, including in the U.S.market, as well as the number of sessions carried out by the Companyin the period, will be presented in the relevant periodic report.

TheManagement Board also informs that it has decided to publish similarestimated data immediatelyafter the end of each subsequentquarter - as soon as such data is prepared, but no later than by themiddle of the month following the end of the given calendar quarter.